Quan Nguyen, MD
Uveitis and Ocular Inflammatory Disease · Stanford, CANPI 1487608766
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.1%), consulting fees and grants — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 35.5% of the total. 2025 is the largest year on record at $141,789, 2.0 times the $70,572 reported in 2019.
Across 560 payments — averaging $1306.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$260K
- Bausch & Lomb Americas Inc.$69K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$54K
- Boehringer Ingelheim International GmbH$45K
- Aerie Pharmaceuticals, Inc.$45K
- Regeneron$35K
- plus $225K from 31 others
Across 211 payments — averaging $10,107 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$838K
- Gilead$353K
- Mallinckrodt Enterprises LLC$268K
- Novartis$218K
- Boehringer Ingelheim$180K
- Biogen$66K
- plus $209K from 8 others
What the payments were for
- Consulting fees$220,49930%
- Speaking & faculty fees$330,31145%
- Grants$98,40013%
- Travel & lodging$65,5159%
- Food & beverage$16,7422%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$278,877
- EYLEA HD$24,828
- EYSUVIS$20,400
- XIPERE$18,278
- Syfovre$14,754
- Lucentis$14,120
- PURIFIED CORTROPHIN GEL$10,901
- EYLEA$9,059
- BEOVU$7,524
- Non-Covered Product$4,159
- RETISERT$3,750
- TRIESENCE$2,937
- VEVYE$2,800
- VABYSMO$2,388
- YUTIQ$2,370
- VISUDYNE$2,250
- STELLARIS$2,250
- OZURDEX$1,097
- STELLARIS ELITE$1,035
- Izervay$483
How this compares
Too few uveitis and ocular inflammatory disease providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 12 | $953,219 |
| Humira(Cf) PenAdalimumab | 21 | $199,767 |
| Humira PenAdalimumab | 16 | $111,615 |
| RestasisCyclosporine | 13 | $12,051 |
| Prednisolone Acetate | 60 | $3,264 |
| Mycophenolate Mofetil | 27 | $3,022 |
| Ketorolac Tromethamine | 76 | $1,910 |
| Acetazolamide | 24 | $1,864 |
| MethotrexateMethotrexate Sodium | 16 | $971 |
| Fluorometholone | 11 | $816 |
| Prednisone | 63 | $803 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $564 |
| Brimonidine Tartrate | 29 | $352 |
| Latanoprost | 25 | $212 |
| Timolol Maleate | 15 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $259,667 | $953,21912 claims |
| AbbVieRestasis | $2,397 | $12,05113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few uveitis and ocular inflammatory disease providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other uveitis and ocular inflammatory disease in Stanford
- Sarju PatelSacramento$97K
- Edmund TsuiLos Angeles$24K
- Olivia LeeIrvine$16K
- Judy ChenPasadena$1K
- Jennifer LeeSantee$555
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.